Boehringer Ingelheim has received a breakthrough therapy designation from the US Food and Drug Administration (FDA) for ...

Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma ...

Boehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new ...

Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Boehringer Ingelheim, Circle Pharma ink research collaboration to develop a novel precision cancer treatment: Ingelheim, Germany Friday, October 11, 2024, 12:00 Hrs [IST] Boehring ...

German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), which is ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif., October 09, 2024--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal to ...